Status:

TERMINATED

Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis

Lead Sponsor:

Corbus Pharmaceuticals Inc.

Conditions:

Diffuse Cutaneous Systemic Sclerosis

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

This is a Phase 3 multicenter, double-blind, randomized, placebo-controlled study assessing the efficacy and safety of lenabasum for the treatment of diffuse cutaneous systemic sclerosis (SSc). Approx...

Eligibility Criteria

Inclusion

  • Key
  • ≥ 18 years of age at the time Informed Consent is signed.
  • Diffuse cutaneous SSc (skin thickening on upper arms, upper legs, or trunk).
  • Disease duration ≤ 6 years from the first non-Raynaud's symptom.
  • No new or increased doses of immunosuppressive medications within 8 weeks prior to Screening.
  • Key

Exclusion

  • Unstable SSc or SSc with end-stage organ involvement at Screening or Visit 1.
  • Any of the following values for laboratory tests at Screening:
  • A positive pregnancy test in women of childbearing potential;
  • Hemoglobin \< 9 g/dL for males and \< 8 g/dL for females;
  • Neutrophils \< 1.0 ×10\^9/L;
  • Platelets \< 75 ×10\^9/L;
  • Creatinine clearance \< 50 mL/min according to the Modification of Diet in Renal Disease (MDRD) Study equation;
  • Aspartate aminotransferase or alanine aminotransferase \> 2.0 × upper limit of normal.
  • Any medical condition or concurrent medical therapies at Screening or Visit 1, including a history of non-compliance with medical treatments, that may put the subject at greater safety risk, influence response to study product, or interfere with study assessments.

Key Trial Info

Start Date :

December 18 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 21 2020

Estimated Enrollment :

365 Patients enrolled

Trial Details

Trial ID

NCT03398837

Start Date

December 18 2017

End Date

December 21 2020

Last Update

March 29 2021

Active Locations (74)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 19 (74 locations)

1

University of California San Diego

La Jolla, California, United States, 92037

2

Pacific Arthritis Care Center

Los Angeles, California, United States, 90045

3

UCLA

Los Angeles, California, United States, 90095

4

Stanford University

Palo Alto, California, United States, 94304

Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis | DecenTrialz